INO — Inovio Pharmaceuticals, Inc.
Is INO overbought or oversold? Here is the current MarketMoodz read.
Inovio Pharmaceuticals, Inc. (INO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.40. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$1.40
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Inovio Pharmaceuticals, Inc. (INO) appears constrained by limited near-term financial visibility, an uncertain clinical pipeline and a macro backdrop that currently favors large-cap, defensive pharma names over small-cap biotech exposure. Convertible-debt and broader sector financing themes raise the prospect of dilution, while sparse public reporting and social/research coverage reduce clarity around imminent positive catalysts. Absent clear, near-term positive data or a capital-raising structure that avoids heavy dilution, downside volatility and execution risk are the primary near-term considerations.
Key factors
- Weak near-term financial visibility and historical cash-burn profile increase refinancing and dilution risk
- Pipeline uncertainty with limited transparent readouts and a history of mixed clinical outcomes
- Sector flows favor large-cap, defensive pharma, reducing investor appetite for small-cap biotech risk
- Convertible-debt and financing dynamics in the biotech sector raise the chance of dilution and hedging pressure
- Limited recent public filings and social/research coverage reduce clarity on catalysts and milestones
Risks
- Major clinical trial failures or negative data releases could trigger steep share price declines
- Necessity of dilutive financing or convertible issuance if cash runway is insufficient
- Regulatory setbacks or delays that push out potential value-driving inflection points
- Low liquidity and elevated volatility can amplify downside moves and reduce orderly price discovery
- Competition from larger, better-funded pharma/biotech players that can capture market share or partner opportunities
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for INO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.